Sign in
Taking people in United StatesNo phase

Flow diverter device for unruptured brain aneurysms in wide-neck shapes

Tests a flow diverter device in adults with unruptured wide-neck brain aneurysms.

Key facts

Who runs it
Stryker Neurovascular
Where
Burlington, Cleveland, Davis, Galveston, Indianapolis, Iowa City, Jacksonville, Kansas City, Los Angeles, Memphis, Miami, New Brunswick, New York, Palo Alto, Philadelphia, Portland, Rochester, Stony Brook, The Bronx, and Tucson, United StatesSee the 20 sites
Trial code
Registry title
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Status
Recruiting
People taking part
183 people, planned
Started
20 Jun 2025
Expected to end
31 Jan 2031
Type of study
Interventional
Treatments tested
  • Surpass Elite with Guardian Flow Diverter System
Record updated
21 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with one unruptured brain aneurysm with a wide neck on the internal carotid artery or its branches. They will be treated with the Surpass Elite with Guardian Flow Diverter System.

Age
18 to 80 years
Sex
All sexes
Disease stage
A single unruptured brain aneurysm of any size, saccular or fusiform. It must sit on the internal carotid artery or its branches. It must have a wide neck (neck width ≥ 4 mm, or dome to neck ratio ≤ 2.0) or no clear neck. The parent blood vessel must measure ≥ 3.0 mm to ≤ 6.0 mm at its widest. Doctors must have documented that treatment through the blood vessels has more benefit than the risk of the aneurysm bursting if left untreated.
Earlier treatment
People cannot join if earlier treatment of the aneurysm or parent artery would get in the way of placing the device. They also cannot join after a brain implant in the same area within the past 84 days.

Main reasons for not taking part

  • Aneurysm in the back part of the brain's blood supply, outside the skull lining, or at a point where a vessel splits
  • Disability score (mRS) of 3 or more, or brain bleeding within the last 30 days
  • Cannot take aspirin, clopidogrel, ticagrelor or heparin, or ongoing blood thinner treatment, or atrial fibrillation
  • Serious other illness, or life expectancy under 5 years
  • Pregnant, breastfeeding, or wishing to become pregnant during the trial

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Age is ≥18 and ≤80 years at the time of consent
  • Has a single unruptured target intracranial aneurysm (IA) of any size with the following characteristics:; Is located on the internal carotid artery or its branches; Has a wide neck (wide neck typically defined as neck width ≥ 4 millimeter (mm), or dome to neck ratio ≤ 2.0) or no discernible neck; Aneurysm is either saccular or fusiform in nature
  • Has a parent vessel diameter ≥ 3.0 mm to ≤ 6.0 mm at the largest diameter
  • There is documented risk-benefit of endovascular treatment that outweighs the risks of intracranial aneurysm rupture during the subject's expected lifetime if left untreated

Who cannot take part

  • Received previous treatment for the target aneurysm or parent artery where it would interfere with the placement or proper apposition of the device
  • Patients with heparin hypersensitivity, including patients with a previous incident of Heparin-Induced Thrombocytopenia (HIT)
  • Presence of unstable neurological deficit (i.e., worsening of clinical condition in the last 30 days prior to the index procedure)
  • Subarachnoid hemorrhage occurred within 30 days prior to the index procedure
  • Major surgery (including previous intracranial implant) either occurred within 30 days prior to the index procedure date or is planned to occur within 120 days following the index procedure date
  • Received previous intracranial implant associated with the symptomatic or vascular distribution within the past 84 days prior to treatment date
  • Chronic anticoagulation therapy is ongoing or known coagulopathy exists
  • Enrollment in another study involving an investigational product that could confound the outcomes of this trial
  • Has a medical contraindication to trial or procedure related antiplatelet medications (aspirin, clopidogrel/Plavix, ticagrelor, and heparin), local or general anesthesia, or life-threatening allergy to contrast dye
  • Has a known severe allergy to nickel, chromium cobalt, tungsten, or platinum
  • Has acute life-threatening illness (e.g., acute kidney or heart failure) other than the neurological disease to be treated in this trial
  • Evidence of active infection at the time of treatment
  • Life expectancy is less than 5 years due to other illness or condition (in addition to an intracranial aneurysm)
  • Unable to comply with the trial follow up requirements due to conditions such as dementia or psychiatric problems, active substance abuse, or history of non-compliance with medical advice, as determined by the investigator
  • Presence of intracranial mass (tumor, except meningioma, abscess, or other infection), non-treated arteriovenous malformation (AVM) in the territory of the target aneurysm
  • Has other known serious concurrent medical conditions such as cardiovascular disease (including recent myocardial infarction [<12 weeks], symptomatic congestive heart failure, or carotid stenosis), kidney failure (>2.0 mg/dl serum creatinine), pulmonary disease, uncontrolled diabetes, progressive neurologic disorders, terminal cancer, vasculitis, high risk of ischemic stroke or recent stroke
  • Has an extradural target aneurysm
  • Has a target aneurysm in the posterior circulation
  • Perforator or branch vessel, inclusive of the posterior communicating artery, arises from the target aneurysm body or neck (branches or arteries must arise or connect from the parent vessel separate from the aneurysm or neck to not be excluded from trial)
  • Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular) located at a point of vessel bifurcation
  • Has vessel characteristics, such as severe tortuosity (cavernous Internal Carotid Artery (cICA) Type IV1), stenosis (>70%), or morphology that would preclude safe endovascular access or proper deployment of the trial device to the target aneurysm
  • Modified Rankin Score (mRS) assessment is ≥ 3 at pre-procedure exam
  • Has more than one intracranial aneurysm (IA) that requires treatment within 12 months after the index procedure
  • Has atrial fibrillation with or without pacemaker
  • Pregnant or breast- feeding women or women who wish to become pregnant during the length of trial participation

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • Lahey Hospital and Medical CenterBurlington, United StatesContact: Sandy AlvarezTaking people
  • Cleveland ClinicCleveland, United StatesContact: Barmen JoyceTaking people
  • University of California Davis HealthDavis, United StatesContact: Savina NguyenTaking people
  • The University of Texas Medical Branch at GalvestonGalveston, United StatesContact: Elizabeth HennesseyTaking people
  • Indiana UniversityIndianapolis, United StatesContact: Lauren SnyderTaking people
  • University of Iowa HealthcareIowa City, United StatesContact: Heena OlaldeTaking people
  • Lyerly Neurosurgery, an Affiliate of BaptistJacksonville, United StatesContact: Karen YesenskyTaking people
  • University of Kansas Medical CenterKansas City, United StatesContact: Max HardenbrookTaking people
  • University of California Los Angeles (UCLA).Los Angeles, United StatesContact: Victoria RuedaTaking people
  • Semmes MurpheyMemphis, United StatesContact: Wendell BarnettTaking people
  • Baptist Hospital of MiamiMiami, United StatesContact: Marianela CruzTaking people
  • Robert Wood Johnson University Medical CenterNew Brunswick, United StatesContact: Christine YohnTaking people
  • Mount Sinai Health SystemNew York, United StatesContact: Emily SvendsenTaking people
  • Stanford University, School of MedicinePalo Alto, United StatesContact: Banu Priya RajasekaranTaking people
  • University of PennsylvaniaPhiladelphia, United StatesContact: Leah CoghlanTaking people
  • Oregon Health Science UniversityPortland, United StatesContact: Emilie NagleTaking people
  • University of Rochester Medical CenterRochester, United StatesContact: Tilor HallquistTaking people
  • Stony Brook University HospitalStony Brook, United StatesContact: Marlene BaumeisterTaking people
  • Montefiore Medical CenterThe Bronx, United StatesContact: Lyanna GomezTaking people
  • Carondelet St. Joseph's HospitalTucson, United StatesContact: Rachael TaokaTaking people

About the trial

What the trial wants to find out

The objective of the Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms with Surpass Elite with GUARDian Flow Diverter (GUARD) trial is to evaluate the safety and efficacy of the Surpass Elite with Guardian Flow Diverter System (FDS) in the treatment of unruptured, wide-neck saccular or fusiform, intracranial aneurysms (IAs) located on the internal carotid artery (ICA) or its branches.

The group in the trial

  • Surpass Elite with Guardian Flow DiverterTreatment being tested

    This is a prospective single arm study in which all subjects who present for Surpass Elite with Guardian flow diverter implantation, provide informed consent, and meet inclusion/exclusion criteria may receive treatment.

    Treatment: Surpass Elite with Guardian Flow Diverter System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter
Plain-language title
Flow diverter device for unruptured brain aneurysms in wide-neck shapesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06872684, who can take part
Record updated
21 October 2026